US FDA approves label updates for Bristol Myers' CAR T cell therapies, Breyanzi for LBCL & lymphomas and Abecma for ...
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other …